Drugs / AUR109
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06760702 | Nov 2024 → Feb 2026 | colorectal cancer, kidney cancer, ovarian cancer | Aurigene Discovery Technologies Limited | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AUR109 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06760702 ↗ |